0001140361-17-046579.txt : 20171218 0001140361-17-046579.hdr.sgml : 20171218 20171218175933 ACCESSION NUMBER: 0001140361-17-046579 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171214 FILED AS OF DATE: 20171218 DATE AS OF CHANGE: 20171218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Benjamin Howard CENTRAL INDEX KEY: 0001393547 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 171262402 MAIL ADDRESS: STREET 1: 401 MARRETT ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 4 1 doc1.xml FORM 4 X0306 4 2017-12-14 0 0000730272 REPLIGEN CORP RGEN 0001393547 Benjamin Howard C/O REPLIGEN CORPORATION 41 SEYON ST, BLDG 1, STE 100 WALTHAM MA 02453 0 1 0 0 VP Business Development Common Stock 2017-12-14 4 M 0 2646 15.91 A 36554 D Common Stock 2017-12-14 4 M 0 6021 26.20 A 42575 D Common Stock 2017-12-14 4 M 0 4062 26.05 A 46637 D Common Stock 2017-12-14 4 S 0 12729 35.3394 D 33908 D Stock Option (Right to Buy) 15.91 2017-12-14 4 M 0 2646 0 D 2024-02-27 Common Stock 2646 0 D Stock Option (Right to Buy) 26.20 2017-12-14 4 M 0 6021 0 D 2025-02-26 Common Stock 6021 3010 D Stock Option (Right to Buy) 26.05 2017-12-14 4 M 0 4062 0 D 2026-02-26 Common Stock 4062 8124 D This option is currently exercisable. $35.3394 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. /s/ Jeffrey P. Leduc (Attorney in Fact) 2017-12-18